We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current BLPH market cap is 795.12k. The company's latest EPS is USD -1.6212 and P/E is -0.06.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -27.88M | -17.47M | -26.28M | -20.16M | -22.38M |
| Net Income | 2.81M | -13.27M | -24.73M | -17.76M | -19.83M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 18.36M | 13.11M | 50.24M | 26.88M | 7.94M |
| Total Liabilities | 14.5M | 9.52M | 11.99M | 5.26M | 5.4M |
| Total Equity | 3.86M | 3.59M | 38.25M | 21.62M | 2.53M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -15.5M | -12.94M | -19.88M | -22.82M | -17.77M |
| Investing | 3M | N/A | N/A | N/A | N/A |
| Financing | 166k | 6.17M | 57.57M | N/A | -40k |
| Market Cap | 795.12k |
| Price to Earnings Ratio | -0.06 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.18 |
| Price to Book Ratio | 0.48 |
| Dividend Yield | - |
| Shares Outstanding | 12.23M |
| Average Volume (1 week) | 32.53k |
| Average Volume (1 Month) | 20.06k |
| 52 Week Change | -18.75% |
| 52 Week High | 0.1025 |
| 52 Week Low | 0.029 |
| Spread (Intraday) | 0 (3.85%) |
| Company Name | Bellerophon Therapeutics Inc (PK) |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.bellerophon.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
